832 related articles for article (PubMed ID: 31715131)
21. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
23. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
24. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
25. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
Crupi MJF; Bell JC; Singaravelu R
Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
[TBL] [Abstract][Full Text] [Related]
26. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
Park JC; Hahn NM
Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
[TBL] [Abstract][Full Text] [Related]
27. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
28. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
29. [Not Available].
Feuchtinger T
Drug Res (Stuttg); 2018 Nov; 68(S 01):S12-S13. PubMed ID: 30453365
[No Abstract] [Full Text] [Related]
30. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
31. Preface: More than two decades of modern tumor immunology.
Galluzzi L; Rudqvist NP
Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
[No Abstract] [Full Text] [Related]
32. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.
Wang L; Yao R; Zhang L; Fan C; Ma L; Liu J
Int Immunopharmacol; 2019 May; 70():498-503. PubMed ID: 30875561
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
34. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Srivastava S; Furlan SN; Jaeger-Ruckstuhl CA; Sarvothama M; Berger C; Smythe KS; Garrison SM; Specht JM; Lee SM; Amezquita RA; Voillet V; Muhunthan V; Yechan-Gunja S; Pillai SPS; Rader C; Houghton AM; Pierce RH; Gottardo R; Maloney DG; Riddell SR
Cancer Cell; 2021 Feb; 39(2):193-208.e10. PubMed ID: 33357452
[TBL] [Abstract][Full Text] [Related]
35. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
36. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
[TBL] [Abstract][Full Text] [Related]
37. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
Front Immunol; 2021; 12():638639. PubMed ID: 34177890
[TBL] [Abstract][Full Text] [Related]
38. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
39. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
Front Immunol; 2022; 13():830292. PubMed ID: 35211124
[TBL] [Abstract][Full Text] [Related]
40. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
